Daré Bioscience, Inc.
DARE
$1.75
$0.031.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -94.48% | -194.64% | 173.12% | -103.52% | -95.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -94.48% | -194.64% | 173.12% | -103.52% | -95.83% |
| Cost of Revenue | -- | -- | -31.65% | -34.04% | -- |
| Gross Profit | -94.48% | -194.64% | 32.22% | 27.68% | -95.72% |
| SG&A Expenses | 22.43% | -2.87% | -13.53% | -32.45% | -24.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.20% | -48.43% | -23.63% | -21.46% | -49.74% |
| Operating Income | 21.56% | 47.99% | 23.93% | -8.38% | 44.25% |
| Income Before Tax | 24.24% | -131.11% | 35.19% | -8.87% | 43.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.24% | -131.11% | 35.19% | -8.87% | 43.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.24% | -131.11% | 35.19% | -8.87% | 43.34% |
| EBIT | 21.56% | 47.99% | 23.93% | -8.38% | 44.25% |
| EBITDA | 31.71% | 54.14% | 26.43% | -8.47% | 44.30% |
| EPS Basic | 49.31% | -129.50% | 38.02% | 0.95% | 49.63% |
| Normalized Basic EPS | 49.30% | -129.50% | 38.03% | -14.37% | 49.62% |
| EPS Diluted | 49.18% | -129.79% | 38.02% | 1.06% | 49.63% |
| Normalized Diluted EPS | 49.30% | -129.73% | 38.03% | -14.37% | 49.62% |
| Average Basic Shares Outstanding | 49.46% | 5.47% | 4.57% | 9.92% | 12.48% |
| Average Diluted Shares Outstanding | 49.46% | 4.66% | 4.57% | 9.92% | 12.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |